E-Selectin inhibitor– Pipeline Insight, 2021
This report can be delivered to the clients within 48 hrs
DelveInsight’s, “E-Selectin inhibitor– Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 7+ pipeline drugs in E-selectin inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
E-SELECTIN inhibitor: Overview
E-Selectin (CD62E or previously referred to as ELAM-1) is a 115 kDa, inducible endothelial cell surface molecule. Its expression on endothelial cells is transcriptionally upregulated by various proinflammatory substances such as IL-1, TNF? and lipopolysaccharide (LPS). Expression of E-selectin on the endothelium is a hallmark of inflammation. E-selectin has been chosen as a target for several therapeutic and medical imaging applications, based on its expression in the vicinity of inflammation, infection or cancer.
Structure- E-selectin is a transmembrane receptor of the selectin family that also contains L- and P-selectins. Two glycosylated forms of E-selectin are detected at 100 and 115 kDa. The primary structure of E-selectin contains several domains: an amino terminal lectin-like domain, followed by an epidermal growth factor (EGF)-like domain and six repeated motifs similar to those found in some complement-binding proteins.
Function – E-Selectin is involved in the accumulation process of blood leukocytes at sites of inflammation by mediating the adhesion of cells to the vascular lining. Adhesion molecules participate in the interaction between leukocytes and the endothelium and appear to be involved in the pathogenesis of atherosclerosis.
E-SELECTIN Inhibitors- In research studies, Inhibiting E-selectin attenuated inflammation in atherosclerotic plaques, likely by reducing leukocyte recruitment into plaques and by mitigating hematopoietic stem and progenitor cell activation in the spleen of mice with myocardial Infarction. Various strategies are studied to exploit and modulate E-selectin-mediated binding include blocking its interaction with its ligands, blocking its ligands and inhibiting the glycosyl transferases associated with biosynthesis of selectin carbohydrate binding determinants. These strategies could inhibit immune and cancer cell adhesion in inflammation and metastasis, respectively.
E-SELECTIN inhibitor Emerging Drugs Chapters
This segment of the E-SELECTIN inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
E-SELECTIN inhibitor Emerging Drugs
Further product details are provided in the report……..
E-SELECTIN inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different E-SELECTIN inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
E-SELECTIN inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses E-SELECTIN inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging E-SELECTIN inhibitor drugs.
Report Highlights
Current Scenario and Emerging Therapies:
DelveInsight’s, “E-Selectin inhibitor– Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 7+ pipeline drugs in E-selectin inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
E-SELECTIN inhibitor: Overview
E-Selectin (CD62E or previously referred to as ELAM-1) is a 115 kDa, inducible endothelial cell surface molecule. Its expression on endothelial cells is transcriptionally upregulated by various proinflammatory substances such as IL-1, TNF? and lipopolysaccharide (LPS). Expression of E-selectin on the endothelium is a hallmark of inflammation. E-selectin has been chosen as a target for several therapeutic and medical imaging applications, based on its expression in the vicinity of inflammation, infection or cancer.
Structure- E-selectin is a transmembrane receptor of the selectin family that also contains L- and P-selectins. Two glycosylated forms of E-selectin are detected at 100 and 115 kDa. The primary structure of E-selectin contains several domains: an amino terminal lectin-like domain, followed by an epidermal growth factor (EGF)-like domain and six repeated motifs similar to those found in some complement-binding proteins.
Function – E-Selectin is involved in the accumulation process of blood leukocytes at sites of inflammation by mediating the adhesion of cells to the vascular lining. Adhesion molecules participate in the interaction between leukocytes and the endothelium and appear to be involved in the pathogenesis of atherosclerosis.
E-SELECTIN Inhibitors- In research studies, Inhibiting E-selectin attenuated inflammation in atherosclerotic plaques, likely by reducing leukocyte recruitment into plaques and by mitigating hematopoietic stem and progenitor cell activation in the spleen of mice with myocardial Infarction. Various strategies are studied to exploit and modulate E-selectin-mediated binding include blocking its interaction with its ligands, blocking its ligands and inhibiting the glycosyl transferases associated with biosynthesis of selectin carbohydrate binding determinants. These strategies could inhibit immune and cancer cell adhesion in inflammation and metastasis, respectively.
E-SELECTIN inhibitor Emerging Drugs Chapters
This segment of the E-SELECTIN inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
E-SELECTIN inhibitor Emerging Drugs
- Uproleselan: GlycoMimetics
- PF-07209326: Pfizer
Further product details are provided in the report……..
E-SELECTIN inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different E-SELECTIN inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on E-SELECTIN inhibitor
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical.
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
E-SELECTIN inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses E-SELECTIN inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging E-SELECTIN inhibitor drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence E-SELECTIN inhibitor R&D. The therapies under development are focused on novel approaches for E-SELECTIN inhibitor.
- In January 2020, GlycoMimetics and Apollomics announce exclusive collaboration and license agreement to develop and commercialize uproleselan and GMI-1687 in Greater China. Under the terms of the agreement, Apollomics will be responsible for clinical development and commercialization in Greater China. GlycoMimetics to receive an upfront cash payment with eligibility to receive development, regulatory, and sales-based milestones, and tiered royalties.
- E-SELECTIN inhibitor Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing E-SELECTIN inhibitor drugs?
- How many E-SELECTIN inhibitor drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for E-SELECTIN inhibitor?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the E-SELECTIN inhibitor therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for E-SELECTIN inhibitor and their status?
- What are the key designations that have been granted to the emerging drugs?
- GlycoMimetics
- Modus Therapeutics
- Pfizer
- Uproleselan
- Rivipansel
- Sevuparin
- GMI-1687
- GMI-1359
- PF-07209326
Introduction
Executive Summary
E-SELECTIN inhibitor: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
E-SELECTIN inhibitor – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
E-SELECTIN inhibitor companies’ collaborations, Licensing, Acquisition -Deal Value Trends
E-SELECTIN inhibitor Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Uproleselan: GlycoMimetics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
PF-07209326: Pfizer
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Pre-clinical and Discovery Stage Products
Comparative Analysis
GMI-1687: GlycoMimetics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
E-SELECTIN inhibitor Key Companies
E-SELECTIN inhibitor Key Products
E-SELECTIN inhibitor- Unmet Needs
E-SELECTIN inhibitor- Market Drivers and Barriers
E-SELECTIN inhibitor- Future Perspectives and Conclusion
E-SELECTIN inhibitor Analyst Views
E-SELECTIN inhibitor Key Companies
Appendix
Executive Summary
E-SELECTIN inhibitor: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
E-SELECTIN inhibitor – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
E-SELECTIN inhibitor companies’ collaborations, Licensing, Acquisition -Deal Value Trends
E-SELECTIN inhibitor Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Uproleselan: GlycoMimetics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
PF-07209326: Pfizer
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Pre-clinical and Discovery Stage Products
Comparative Analysis
GMI-1687: GlycoMimetics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
E-SELECTIN inhibitor Key Companies
E-SELECTIN inhibitor Key Products
E-SELECTIN inhibitor- Unmet Needs
E-SELECTIN inhibitor- Market Drivers and Barriers
E-SELECTIN inhibitor- Future Perspectives and Conclusion
E-SELECTIN inhibitor Analyst Views
E-SELECTIN inhibitor Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for E-SELECTIN inhibitor
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for E-SELECTIN inhibitor
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for E-SELECTIN inhibitor
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for E-SELECTIN inhibitor
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
